L13

General Information


DRACP ID  DRACP00065

Peptide Name   L13

Sequence  PAWRKAFRKAWRMLKKAA

Sequence Length  18

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Meth A Mouse fibrosarcoma Sarcoma IC50=14 µM MTT assay 4 h 1
MT-1 Human mammary carcinoma Carcinoma IC50=12 µM MTT assay 4 h 1
HT-29 Colon adenocarcinoma Carcinoma IC50=29 µM MTT assay 4 h 1

Hemolytic Activity  Human red blood cells: EC50>451 µM

Normal (non-cancerous) Cytotoxicity  Fibroblas: IC50=59 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00065

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C104H167N33O19S

Absent amino acids  CDEGHINQSTVY

Common amino acids  A

Mass  251915

Pl  12.83

Basic residues  7

Acidic residues  0

Hydrophobic residues  9

Net charge  7

Boman Index  -4300

Hydrophobicity  -83.33

Aliphatic Index  49.44

Half Life 
  Mammalian: >20 hour
  Yeast: >20 hour
  E.coli: ?

Extinction Coefficient cystines  11000

Absorbance 280nm  647.06

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 12366526

Title  Enhanced antitumor activity and selectivity of lactoferrin-derived peptides

Doi 10.1034/j.1399-3011.2002.21008.x

Year  2002

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.